Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis

Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuleerarux, Nipat, Manothummetha, Kasama, Moonla, Chatphatai, Sanguankeo, Anawin, Kates, Olivia S., Hirankarn, Nattiya, Phongkhun, Kasidis, Thanakitcharu, Jaedvara, Leksuwankun, Surachai, Meejun, Tanaporn, Thongkam, Achitpol, Mongkolkaew, Thanuthong, Dioverti, M. Veronica, Torvorapanit, Pattama, Langsiri, Nattapong, Worasilchai, Navaporn, Plongla, Rongpong, Chindamporn, Ariya, Gopinath, Shilpa, Nissaisorakarn, Pitchaphon, Thaniyavarn, Tany, Nematollahi, Saman, Permpalung, Nitipong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561400/
https://www.ncbi.nlm.nih.gov/pubmed/36538342
http://dx.doi.org/10.1182/bloodadvances.2022008530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561400/
https://www.ncbi.nlm.nih.gov/pubmed/36538342
http://dx.doi.org/10.1182/bloodadvances.2022008530

Ejemplares similares